Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Immunovant downgraded to Neutral from Buy at UBS » 05:29
09/26/22
09/26
05:29
09/26/22
05:29
IMVT

Immunovant

$4.88 /

-0.24 (-4.69%)

, ARGX

Argenx

$343.20 /

-14.4 (-4.03%)

, JNJ

Johnson & Johnson

$166.96 /

+0.825 (+0.50%)

UBS analyst Colin Bristow…

UBS analyst Colin Bristow downgraded Immunovant (IMVT) to Neutral from Buy with a price target of $5, down from $7. The analyst sees no major clinical catalysts or updaters until the second half of 2023. In addition, Immunovant is facing increasing neonatal Fc receptor competition as competitors Argenx (ARGX) and Johnson & Johnson (JNJ) continue to move into new indications, Bristow tells investors in a research note. The analyst acknowledges Immunovant is trading $1-$2 per share above cash but says ultimately "this cash reserve is committed to fund batoclimab development."

ShowHide Related Items >><<
JNJ Johnson & Johnson
$166.96 /

+0.825 (+0.50%)

IMVT Immunovant
$4.88 /

-0.24 (-4.69%)

ARGX Argenx
$343.20 /

-14.4 (-4.03%)

IMVT Immunovant
$4.88 /

-0.24 (-4.69%)

03/30/22 Chardan
Immunovant price target lowered to $14 from $20 at Chardan
01/05/22 Chardan
Immunovant price target lowered to $20 from $22 at Chardan
12/31/21 Wells Fargo
Immunovant shares to remain range-bound in 2022, says Wells Fargo
12/08/21 Wells Fargo
Immunovant initiated with an Equal Weight at Wells Fargo
ARGX Argenx
$343.20 /

-14.4 (-4.03%)

09/22/22 Deutsche Bank
Argenx price target raised to EUR 425 from EUR 400 at Deutsche Bank
08/26/22 Piper Sandler
Argenx price target raised to $465 from $450 at Piper Sandler
08/10/22 Barclays
Argenx price target raised to EUR 405 from EUR 390 at Barclays
08/05/22 JPMorgan
Argenx price target raised to C$470 from C$430 at JPMorgan
JNJ Johnson & Johnson
$166.96 /

+0.825 (+0.50%)

07/21/22 UBS
Johnson & Johnson price target lowered to $180 from $185 at UBS
07/20/22 SVB Securities
Johnson & Johnson price target lowered to $194 from $200 at SVB Securities
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Citi
Johnson & Johnson price target lowered to $201 from $205 at Citi
JNJ Johnson & Johnson
$166.96 /

+0.825 (+0.50%)

IMVT Immunovant
$4.88 /

-0.24 (-4.69%)

ARGX Argenx
$343.20 /

-14.4 (-4.03%)

  • 24
    Mar
JNJ Johnson & Johnson
$166.96 /

+0.825 (+0.50%)

JNJ Johnson & Johnson
$166.96 /

+0.825 (+0.50%)

ARGX Argenx
$343.20 /

-14.4 (-4.03%)

JNJ Johnson & Johnson
$166.96 /

+0.825 (+0.50%)

Recommendations
Argenx price target raised to EUR 425 from EUR 400 at Deutsche Bank » 14:37
09/22/22
09/22
14:37
09/22/22
14:37
ARGX

Argenx

$357.19 /

-4.23 (-1.17%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis raised the firm's price target on Argenx to EUR 425 from EUR 400 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
ARGX Argenx
$357.19 /

-4.23 (-1.17%)

ARGX Argenx
$357.19 /

-4.23 (-1.17%)

08/26/22 Piper Sandler
Argenx price target raised to $465 from $450 at Piper Sandler
08/10/22 Barclays
Argenx price target raised to EUR 405 from EUR 390 at Barclays
08/05/22 JPMorgan
Argenx price target raised to C$470 from C$430 at JPMorgan
07/29/22 H.C. Wainwright
Argenx price target raised to $425 from $400 at H.C. Wainwright
ARGX Argenx
$357.19 /

-4.23 (-1.17%)

  • 24
    Mar
ARGX Argenx
$357.19 /

-4.23 (-1.17%)

Conference/Events
Argenx to participate in a conference call with JPMorgan » 10:55
09/22/22
09/22
10:55
09/22/22
10:55
ARGX

Argenx

$355.96 /

-5.46 (-1.51%)

Conference call with CEO…

Conference call with CEO Hauwermeiren to be held on September 22 at 11 am. Webcast Link

ShowHide Related Items >><<
ARGX Argenx
$355.96 /

-5.46 (-1.51%)

ARGX Argenx
$355.96 /

-5.46 (-1.51%)

08/26/22 Piper Sandler
Argenx price target raised to $465 from $450 at Piper Sandler
08/10/22 Barclays
Argenx price target raised to EUR 405 from EUR 390 at Barclays
08/05/22 JPMorgan
Argenx price target raised to C$470 from C$430 at JPMorgan
07/29/22 H.C. Wainwright
Argenx price target raised to $425 from $400 at H.C. Wainwright
ARGX Argenx
$355.96 /

-5.46 (-1.51%)

  • 24
    Mar
ARGX Argenx
$355.96 /

-5.46 (-1.51%)

Conference/Events
Argenx to participate in a conference call with JPMorgan » 09:59
09/22/22
09/22
09:59
09/22/22
09:59
ARGX

Argenx

$355.72 /

-5.7 (-1.58%)

Conference call with CEO…

Conference call with CEO Hauwermeiren to be held on September 22 at 11 am. Webcast Link

ShowHide Related Items >><<
ARGX Argenx
$355.72 /

-5.7 (-1.58%)

ARGX Argenx
$355.72 /

-5.7 (-1.58%)

08/26/22 Piper Sandler
Argenx price target raised to $465 from $450 at Piper Sandler
08/10/22 Barclays
Argenx price target raised to EUR 405 from EUR 390 at Barclays
08/05/22 JPMorgan
Argenx price target raised to C$470 from C$430 at JPMorgan
07/29/22 H.C. Wainwright
Argenx price target raised to $425 from $400 at H.C. Wainwright
ARGX Argenx
$355.72 /

-5.7 (-1.58%)

  • 24
    Mar
ARGX Argenx
$355.72 /

-5.7 (-1.58%)

Hot Stocks
Argenx submits SC efgartigimod BLA to FDA » 05:27
09/21/22
09/21
05:27
09/21/22
05:27
ARGX

Argenx

$370.15 /

+7.01 (+1.93%)

, HALO

Halozyme

$40.32 /

-0.55 (-1.35%)

Argenx (ARGX) announced…

Argenx (ARGX) announced the submission of a Biologics License Application, or BLA, to the FDA for SC efgartigimod for the treatment of generalized myasthenia gravis, or gMG, in adult patients. SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20, Halozyme's (HALO) Enhanze drug delivery technology. Enhanze facilitates the subcutaneous injection delivery of biologics that are typically administered via intravenous, or IV, infusion.

ShowHide Related Items >><<
HALO Halozyme
$40.32 /

-0.55 (-1.35%)

ARGX Argenx
$370.15 /

+7.01 (+1.93%)

ARGX Argenx
$370.15 /

+7.01 (+1.93%)

08/26/22 Piper Sandler
Argenx price target raised to $465 from $450 at Piper Sandler
08/10/22 Barclays
Argenx price target raised to EUR 405 from EUR 390 at Barclays
08/05/22 JPMorgan
Argenx price target raised to C$470 from C$430 at JPMorgan
07/29/22 H.C. Wainwright
Argenx price target raised to $425 from $400 at H.C. Wainwright
HALO Halozyme
$40.32 /

-0.55 (-1.35%)

09/09/22 Morgan Stanley
Halozyme initiated with an Overweight at Morgan Stanley
08/10/22 Benchmark
Halozyme recent weakness a buying opportunity, says Benchmark
05/23/22 SVB Securities
Halozyme initiated with an Outperform at SVB Leerink
04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
HALO Halozyme
$40.32 /

-0.55 (-1.35%)

ARGX Argenx
$370.15 /

+7.01 (+1.93%)

  • 24
    Mar
HALO Halozyme
$40.32 /

-0.55 (-1.35%)

ARGX Argenx
$370.15 /

+7.01 (+1.93%)

Over a month ago
Recommendations
Argenx price target raised to $465 from $450 at Piper Sandler » 04:41
08/26/22
08/26
04:41
08/26/22
04:41
ARGX

Argenx

$394.28 /

-0.62 (-0.16%)

Piper Sandler analyst…

Piper Sandler analyst Allison Bratzel raised the firm's price target on Argenx to $465 from $450 and keeps an Overweight rating on the shares. The analyst says her two neurologist surveys focused on Vyvgart's generalized myasthenia gravis launch were "quite bullish." The feedback indicates a "bolus of initial demand among refractory patients driving early uptake," which bodes well for Vyvgart, Bratzel tells investors in a research note. The analyst raised her 2022 worldwide Vyvgart revenue estimate to $375M, well ahead of the consensus estimate of $339M.

ShowHide Related Items >><<
ARGX Argenx
$394.28 /

-0.62 (-0.16%)

ARGX Argenx
$394.28 /

-0.62 (-0.16%)

08/10/22 Barclays
Argenx price target raised to EUR 405 from EUR 390 at Barclays
08/05/22 JPMorgan
Argenx price target raised to C$470 from C$430 at JPMorgan
07/29/22 H.C. Wainwright
Argenx price target raised to $425 from $400 at H.C. Wainwright
07/29/22 Baird
Argenx downgraded to Neutral at Baird with positives seen priced in
ARGX Argenx
$394.28 /

-0.62 (-0.16%)

  • 24
    Mar
ARGX Argenx
$394.28 /

-0.62 (-0.16%)

Hot Stocks
Argenx announces European Commission approval of VYVGART » 07:29
08/11/22
08/11
07:29
08/11/22
07:29
ARGX

Argenx

$374.44 /

+1.875 (+0.50%)

argenx announced that the…

argenx announced that the European Commission has granted marketing authorization for VYVGART as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive. The approval is applicable to all 27 European Union Member States plus Iceland, Norway and Liechtenstein. argenx will work with local health authorities to secure market access for VYVGART across the EU.

ShowHide Related Items >><<
ARGX Argenx
$374.44 /

+1.875 (+0.50%)

ARGX Argenx
$374.44 /

+1.875 (+0.50%)

08/10/22 Barclays
Argenx price target raised to EUR 405 from EUR 390 at Barclays
08/05/22 JPMorgan
Argenx price target raised to C$470 from C$430 at JPMorgan
07/29/22 H.C. Wainwright
Argenx price target raised to $425 from $400 at H.C. Wainwright
07/29/22 Baird
Argenx downgraded to Neutral at Baird with positives seen priced in
ARGX Argenx
$374.44 /

+1.875 (+0.50%)

  • 24
    Mar
ARGX Argenx
$374.44 /

+1.875 (+0.50%)

Recommendations
Argenx price target raised to EUR 405 from EUR 390 at Barclays » 15:12
08/10/22
08/10
15:12
08/10/22
15:12
ARGX

Argenx

$369.38 /

-3.185 (-0.85%)

Barclays analyst Emily…

Barclays analyst Emily Field raised the firm's price target on Argenx to EUR 405 from EUR 390 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
ARGX Argenx
$369.38 /

-3.185 (-0.85%)

ARGX Argenx
$369.38 /

-3.185 (-0.85%)

08/05/22 JPMorgan
Argenx price target raised to C$470 from C$430 at JPMorgan
07/29/22 H.C. Wainwright
Argenx price target raised to $425 from $400 at H.C. Wainwright
07/29/22 Baird
Argenx downgraded to Neutral at Baird with positives seen priced in
07/28/22 Baird
Argenx downgraded to Neutral from Outperform at Baird
ARGX Argenx
$369.38 /

-3.185 (-0.85%)

  • 24
    Mar
ARGX Argenx
$369.38 /

-3.185 (-0.85%)

Recommendations
Argenx price target raised to C$470 from C$430 at JPMorgan » 11:16
08/05/22
08/05
11:16
08/05/22
11:16
ARGX

Argenx

$366.29 /

+1.11 (+0.30%)

JPMorgan analyst James…

JPMorgan analyst James Gordon raised the firm's price target on Argenx to C$470 from C$430 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
ARGX Argenx
$366.29 /

+1.11 (+0.30%)

ARGX Argenx
$366.29 /

+1.11 (+0.30%)

07/29/22 H.C. Wainwright
Argenx price target raised to $425 from $400 at H.C. Wainwright
07/29/22 Baird
Argenx downgraded to Neutral at Baird with positives seen priced in
07/28/22 Baird
Argenx downgraded to Neutral from Outperform at Baird
07/28/22 Piper Sandler
Argenx price target raised to $450 from $425 at Piper Sandler
ARGX Argenx
$366.29 /

+1.11 (+0.30%)

  • 24
    Mar
ARGX Argenx
$366.29 /

+1.11 (+0.30%)

Recommendations
Argenx price target raised to $425 from $400 at H.C. Wainwright » 08:33
07/29/22
07/29
08:33
07/29/22
08:33
ARGX

Argenx

$373.40 /

+15.62 (+4.37%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Argenx to $425 from $400 and keeps a Buy rating on the shares. While he's been bullish on Vyvart and "confident that it would achieve blockbuster status," he would have readily admitted at the beginning of the year that there was some uncertainty regarding the shape of its launch curve as a first-in-class drug, Tsao tells investors. However, given that sales in Q2 were nearly times his estimate, he thinks it is "becoming obvious that Vyvgart is going to be a blockbuster sooner rather than later," the analyst added.

ShowHide Related Items >><<
ARGX Argenx
$373.40 /

+15.62 (+4.37%)

ARGX Argenx
$373.40 /

+15.62 (+4.37%)

07/29/22 Baird
Argenx downgraded to Neutral at Baird with positives seen priced in
07/28/22 Baird
Argenx downgraded to Neutral from Outperform at Baird
07/28/22 Piper Sandler
Argenx price target raised to $450 from $425 at Piper Sandler
07/28/22 Stifel
Argenx price target raised to $471 from $460 at Stifel
ARGX Argenx
$373.40 /

+15.62 (+4.37%)

  • 24
    Mar
ARGX Argenx
$373.40 /

+15.62 (+4.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.